A family office based in California invests in primarily early-stage (seed, Series A) companies with truly innovative technologies with a typical investment size of $2-5M per company and can invest as low as $500K. The firm will generally lead investments, and invests globally with no geographic preference.

The firm is seeking innovative technology that is outside traditional biotech. The company is agnostic across life science sectors, including therapeutics, devices, and tools, but will not look at Healthcare IT or digital health technologies. They are interested in therapeutics targeting novel first-in-class targets, and not in biosimilars or repurposed drugs. The firm focuses on early stage preclinical to clinical-stage technology, though may be open to commercial-stage technology depending on the opportunity.

The firm is seeking companies with founders who have big ambitions, and a demonstrated ability to sell their team, investors, and partners on their vision. Previous startup experience is a big plus, but not required, and they will invest in young and first-time entrepreneurs.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A large biotechnology company headquartered in the USA is continuously looking to expand its pipeline through external partnerships and is open to many types of collaboration, including e.g. collaborative research, equity investments, licensing, or M&A. The company considers opportunities from around the globe.

The firm is currently focused on neurodegenerative diseases, neuromuscular disorders, pain, neuroimmunology/-inflammation, other rare neurological diseases, and adjacencies to neurology such as ophthalmology; and other rare and orphan diseases. The firm is seeking platform technologies (e.g. gene therapy/editing) as well as single therapeutic assets that facilitate the identification and validation of new therapeutic targets, biomarkers and patient segmentation strategies. The firm considers projects from post-lead identification and pre-IND to late clinical stages, with an increased interest in Phase Ib and later projects.

Along this line, the company is also interested in diagnostic tools to utilize biomarkers of interest early in clinical trials. The firm is modality agnostic with respect to therapeutic approaches. The firm evaluates deal opportunities on a case-by-case basis, considering a wide range of opportunities from early academic partnerships to M&A.

The firm principally evaluates opportunities based on three key criteria: transformative (‘moonshot’) solution to unmet medical need, sound scientific basis, and clear clinical development and regulatory pathways.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A venture capital firm with offices worldwide closed a new fund in 2017. The firm predominantly focuses on seed and series A and B investments in early stage biotechnology companies, as well as growth equity investments in medical devices companies. The firm’s typical investment size for early stage companies is $5M-$15M and the firm can allocate up to $35-40M total over the life of an investment. The firm focuses on companies that are based in the U.S., Canada and Europe and is actively seeking new investment opportunities.

The firm’s newest fund closed at $400 million, and will invest in 20‐25 biotechnology companies in the U.S., Canada and Europe.

The firm focuses on novel therapeutics and is opportunistic in terms of subsectors and indications. The firm is interested in novel small molecule and biologic therapeutics that address immuno-oncology, orphan/rare or genetic-based diseases, inflammation, infectious diseases and specific viruses, microbiome, and fibrosis and CNS indications. The firm is also interested in regenerative medicine and gene therapy. In medical devices, the firm is generally agnostic to subsector, but is more interested in revenue-generating devices that address cardiovascular, orthopedic, ophthalmic and neurological disorders. Versant prefers devices with proof-of-concept and strong IP.

The firm prefers that a startup company has a strong and experienced management team or technical experts in the relevant technology. The firm generally is flexible with management teams.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A venture capital and private equity firm based in Shanghai, China manages both US dollar and RMB denominated fund. The firm invests in Series A rounds at $1-2M, though its sweet spot is investing $10-15M in Series B/C rounds. The firm works closely with local provincial Chinese governments, allowing them the ability to bring technology successfully into the Chinese market. The firm will generally not invest in the seed stage, and seeks opportunities globally.

The firm invests in pharmaceuticals and Class II medical devices, including an interest in 505(b)(2) repurposed compounds, as well as healthcare-related industries. The firm is interested in all therapeutic areas and in early to mid development stage companies. The firm focuses on unmet medical needs with a China market potential.

The firm does not have management team requirements. The firm will typically take a board seat post-investment, and has the capability to lead and co-invest.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A family office based in the southeast USA focuses its investment interests in healthcare, real estate, energy, and IT. The firm makes equity investments ranging from early-stage to full on commercialization, but also provides debt and convertible loan financing. The firm generally looks for USA-based opportunities but may consider deals outside of the USA and has a track record of working with companies globally. The firm seeks to make approximately 6-10 investments per year.

In the life sciences, the firm has a strong interest in medical device and diagnostic companies. The firm considers healthcare IT opportunities to a lesser degree, and will not consider biopharma companies for the most part. The firm is open to devices of all FDA regulatory pathways including 510k and PMA. The firm is very opportunistic regarding the company’s stage of development and will consider products that are both on- and off-market.

The firm is looking for privately held companies backed by an experienced management team. Companies should have a strong exit strategy, including having a direct line of contact with strategic or financial buyers. The firm is open to both leading and co-investing in a financing round.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A California-based venture capital firm was founded in 2014 by a parent company based in China. The firm’s strong connection with Chinese partners enables the firm to support companies with market entry in China. The firm prefers to participate in seed/pre-series A financing rounds with check sizes of no larger than $500K, and hopes to invest more capital in later rounds (i.e. Series A to B) as follow on investments to portfolio companies. The firm seeks investment opportunities globally.

The firm is opportunistic and will seek companies in all parts of the life sciences space: therapeutics, medical devices, diagnostics, healthcare IT, etc. The firm has not invested in therapeutic products so far but is actively seeking new opportunities in the biopharma space, focusing on pre-clinical to phase I assets. The firm focuses on early-stage deals and will consider pre-FDA device products. The firm is open to companies developing products in all indications.

The firm seeks to work with privately owned companies with experienced management teams with a track record of success. The firm likes to see companies with intentions of entering the China market as the firm has a network of resources to support this, but this is not a requirement. The firm generally acts as the co-investor in financing rounds.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A venture capital firm with offices worldwide closed a $500M fund in 2016. The firm invests mainly in early-stage technology companies (i.e. internet, SaaS, consumer-tech, etc.) with high disruptive potential and seeks to be the first institutional investor, but dedicates a small amount of capital (about 20% of the fund) to later-stage companies as well. Typically, first checks fall in the $2-5M range in Seed to Series A rounds, but the firm has made investments as small as $250K. Overall, the firm invests in over 20 companies per year across North America and Asia. In terms of healthtech specifically, the firm makes 1-2 USA-based and 1 China-based investments per year.

In the healthcare sector, the firm is mainly interested in healthcare IT opportunities and will not consider therapeutics or medical devices. The firm will stray away from anything that involves FDA regulatory approval. Previous investments of the firm have included tools to improve physician workflow, healthcare AI applications, and wearable health trackers for a consumer market. Companies do not need to be generating revenue prior to investment.

The firm invests in private companies with strong technology and can work with different kinds of management teams that are ideally devoted full-time to the company. The firm will almost always act as the lead investor and seek board representation, staying actively involved in their portfolio companies. The firm prefers to have a syndicate of co-investors invest alongside the firm, but this is not an absolute requirement.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com